$PDEX
PRO DEX INC Stock $pdex

$pdex Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000155335024000079 Filed on September 05, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$14.89M	$15.03M	$53.84M
YoY Change	24.74%	41.21%	16.83%
Cost Of Revenue	$9.742M	$10.94M	$39.29M
YoY Change	17.66%	50.22%	17.86%
Gross Profit	$5.150M	$4.089M	$14.55M
YoY Change	40.79%	21.7%	14.13%
Gross Profit Margin	34.58%	27.21%	27.02%
Selling, General & Admin	$1.294M	$902.0K	$4.189M
YoY Change	26.86%	-14.1%	0.14%
% of Gross Profit	25.13%	22.06%	28.79%
Research & Development	$843.0K	$836.0K	$3.189M
YoY Change	4.72%	19.43%	13.73%
% of Gross Profit	16.37%	20.45%	21.92%
Depreciation & Amortization	$302.0K	$306.0K	$1.160M
YoY Change	7.09%	13.33%	35.36%
% of Gross Profit	5.86%	7.48%	7.97%
Operating Expenses	$2.137M	$1.738M	$7.378M
YoY Change	17.1%	-0.69%	5.6%
Operating Profit	$3.013M	$2.351M	$7.173M
YoY Change	64.38%	46.02%	24.49%
Interest Expense	$152.0K	-$421.0K	-$4.539M
YoY Change	14.29%	-111.76%	-951.59%
% of Operating Profit	5.04%	-17.91%	-63.28%
Other Income/Expense, Net			-$4.539M
YoY Change			-223.81%
Pretax Income	$3.319M	$1.930M	$2.634M
YoY Change	-500.36%	-62.81%	-72.06%
Income Tax	$853.0K	$343.0K	$507.0K
% Of Pretax Income	25.7%	17.77%	19.25%
Net Earnings	$2.466M	$1.587M	$2.127M
YoY Change	-500.98%	-58.35%	-69.93%
Net Earnings / Revenue	16.56%	10.56%	3.95%
Basic Earnings Per Share	$0.76		$0.61
Diluted Earnings Per Share	$0.75	$0.46	$0.60
COMMON SHARES
Basic Shares Outstanding	3.358M shares	3.419M shares	3.499M shares
Diluted Shares Outstanding	3.292M shares		3.571M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.294M	$8.411M	$6.848M
YoY Change	16.09%	-27.44%	68.26%
Cash & Equivalents	$3.081M	$2.631M	$2.631M
Short-Term Investments	$6.213M	$5.780M	$4.217M
Other Short-Term Assets	$623.0K	$607.0K	$607.0K
YoY Change	-21.14%	-23.16%	-23.16%
Inventory	$16.60M	$15.27M	$15.27M
Prepaid Expenses		$345.0K
Receivables	$13.46M	$13.89M	$13.89M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$38.50M	$36.61M	$36.61M
YoY Change	22.52%	18.18%	18.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.183M	$5.024M	$12.65M
YoY Change	4.66%	-1.08%	-4.15%
Goodwill
YoY Change
Intangibles	$47.00K	$54.00K
YoY Change	-37.33%	-33.33%
Long-Term Investments	$1.475M	$1.563M	$1.563M
YoY Change	-71.02%	-79.22%	-79.22%
Other Assets	$44.00K	$42.00K	$1.597M
YoY Change	4.76%	0.0%	3892.5%
Total Long-Term Assets	$15.81M	$15.87M	$15.87M
YoY Change	-12.97%	-23.88%	-23.87%
TOTAL ASSETS
Total Short-Term Assets	$38.50M	$36.61M	$36.61M
Total Long-Term Assets	$15.81M	$15.87M	$15.87M
Total Assets	$54.31M	$52.48M	$52.48M
YoY Change	9.53%	1.26%	1.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.442M	$4.513M	$4.513M
YoY Change	62.12%	99.6%	99.69%
Accrued Expenses	$4.019M	$3.359M	$3.359M
YoY Change	48.8%	7.15%	6.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.401M	$4.374M	$4.374M
YoY Change	-15.46%	14.2%	14.2%
Total Short-Term Liabilities	$11.29M	$12.89M	$12.89M
YoY Change	36.28%	33.24%	33.18%
LONG-TERM LIABILITIES
Long-Term Debt	$11.08M	$7.536M	$7.536M
YoY Change	29.32%	-15.42%	-15.42%
Other Long-Term Liabilities	$1.063M	$1.182M	$1.182M
YoY Change	-30.52%	-27.93%	-27.93%
Total Long-Term Liabilities	$12.15M	$8.718M	$8.718M
YoY Change	20.15%	-17.42%	-17.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.29M	$12.89M	$12.89M
Total Long-Term Liabilities	$12.15M	$8.718M	$8.718M
Total Liabilities	$23.43M	$21.61M	$21.61M
YoY Change	27.41%	6.81%	6.82%
SHAREHOLDERS EQUITY
Retained Earnings	$29.42M	$26.95M
YoY Change	21.51%	8.57%
Common Stock	$1.461M	$3.917M
YoY Change	-79.09%	-42.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.88M	$30.87M	$30.87M
YoY Change
Total Liabilities & Shareholders Equity	$54.31M	$52.48M	$52.48M
YoY Change	9.53%	1.26%	1.27%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	$2.466M	$1.587M	$2.127M
YoY Change	-500.98%	-58.35%	-69.93%
Depreciation, Depletion And Amortization	$302.0K	$306.0K	$1.160M
YoY Change	7.09%	13.33%	35.36%
Cash From Operating Activities	$1.887M	$1.020M	$6.199M
YoY Change	381.38%	64.52%	13.49%
INVESTING ACTIVITIES
Capital Expenditures	$431.0K	$107.0K	$983.0K
YoY Change	242.06%	-28.67%	1.34%
Acquisitions
YoY Change
Other Investing Activities		$0.00	-$1.250M
YoY Change			-1488.89%
Cash From Investing Activities	-$431.0K	-$107.0K	-$2.233M
YoY Change	242.06%	-33.12%	152.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.505M
YoY Change			126.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.006M	-1.501M	-$4.271M
YoY Change	-22.5%	-505.68%	71.53%
NET CHANGE
Cash From Operating Activities	$1.887M	1.020M	$6.199M
Cash From Investing Activities	-$431.0K	-107.0K	-$2.233M
Cash From Financing Activities	-$1.006M	-1.501M	-$4.271M
Net Change In Cash	$450.0K	-588.0K	-$305.0K
YoY Change	-143.6%	-170.84%	-114.61%
FREE CASH FLOW
Cash From Operating Activities	$1.887M	$1.020M	$6.199M
Capital Expenditures	$431.0K	$107.0K	$983.0K
Free Cash Flow	$1.456M	$913.0K	$5.216M
YoY Change	447.37%	94.26%	16.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000788920
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	pdex	Stock Issued During Period Value With Performance Award Vesting StockIssuedDuringPeriodValueWithPerformanceAwardVesting		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	35500000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3358057	shares
CY2024	dei	Auditor Firm AuditorFirmId	659
CY2024	dei	Auditor Name AuditorName	Moss Adams LLP
CY2024	dei	Auditor Location AuditorLocation	Irvine, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2631000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2936000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	4217000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	1134000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13887000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9952000	usd
CY2024Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	262000	usd
CY2023Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	494000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	15269000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	16167000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	345000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	296000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	36611000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	30979000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6155000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6249000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5024000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5079000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1473000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1872000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	54000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	81000	usd
CY2024Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1555000	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	1563000	usd
CY2023Q2	us-gaap	Long Term Investments LongTermInvestments	7521000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2024Q2	us-gaap	Assets Assets	52477000	usd
CY2023Q2	us-gaap	Assets Assets	51823000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4513000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2261000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3359000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3135000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	632000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	453000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4374000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	3827000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12892000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9676000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1182000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1638000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	7536000	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	8911000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8718000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10557000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	21610000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	20233000	usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3363412	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3363412	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3545309	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3545309	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3917000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6767000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26950000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	24823000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	30867000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31590000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52477000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51823000	usd
CY2024	us-gaap	Revenues Revenues	53844000	usd
CY2023	us-gaap	Revenues Revenues	46087000	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	39293000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	33338000	usd
CY2024	us-gaap	Gross Profit GrossProfit	14551000	usd
CY2023	us-gaap	Gross Profit GrossProfit	12749000	usd
CY2024	us-gaap	Selling Expense SellingExpense	117000	usd
CY2023	us-gaap	Selling Expense SellingExpense	155000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4072000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4028000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	7173000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	5762000	usd
CY2024	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	144000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	294000	usd
CY2024	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4125000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3899000	usd
CY2024	pdex	Gain Loss On Investment GainLossOnInvestment	0	usd
CY2023	pdex	Gain Loss On Investment GainLossOnInvestment	6000	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	558000	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	533000	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4539000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3666000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2634000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	507000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2354000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	2127000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	7074000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.98
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.95
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3498807	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3571044	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3571207	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3636944	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25431000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	7074000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	77000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	223000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	766000	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1547000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31590000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	2127000	usd
CY2024	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	50000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	605000	usd
CY2024	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3505000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	30867000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	2127000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	7074000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1160000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	857000	usd
CY2024	pdex	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investment UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestment	-4125000	usd
CY2023	pdex	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investment UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestment	3899000	usd
CY2024	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	-0	usd
CY2023	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	6000	usd
CY2024	pdex	Noncash Lease Recovery NoncashLeaseRecovery	-17000	usd
CY2023	pdex	Noncash Lease Recovery NoncashLeaseRecovery	-2000	usd
CY2024	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	13000	usd
CY2023	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-12000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	605000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	766000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1563000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	264000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3935000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5432000	usd
CY2024	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-232000	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-216000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-898000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3489000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	49000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-494000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2436000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1153000	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	14000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1013000	usd
CY2024	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	179000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-91000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6199000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5462000	usd
CY2024	pdex	Payment To Acquire Property Plant And Equipment PaymentToAcquirePropertyPlantAndEquipment	983000	usd
CY2023	pdex	Payment To Acquire Property Plant And Equipment PaymentToAcquirePropertyPlantAndEquipment	974000	usd
CY2024	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	89000	usd
CY2024	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1250000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2233000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-885000	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4816000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6093000	usd
CY2024	pdex	Borrowing From Minnesota Bank Trust Net Of Loan Origination Fees BorrowingFromMinnesotaBankTrustNetOfLoanOriginationFees	4000000	usd
CY2023	pdex	Borrowing From Minnesota Bank Trust Net Of Loan Origination Fees BorrowingFromMinnesotaBankTrustNetOfLoanOriginationFees	5284000	usd
CY2024	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3505000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1547000	usd
CY2024	pdex	Payments Of Employee Taxes On Net Issuance Of Common Stock PaymentsOfEmployeeTaxesOnNetIssuanceOfCommonStock	0	usd
CY2023	pdex	Payments Of Employee Taxes On Net Issuance Of Common Stock PaymentsOfEmployeeTaxesOnNetIssuanceOfCommonStock	-223000	usd
CY2024	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	50000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	89000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4271000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2490000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-305000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2087000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2936000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	849000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2631000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2936000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1891000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1655000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	555000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	521000	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zvnqsU1pwBce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">1.</td><td style="text-align: justify"><span id="xdx_82C_zTzFjsPcMvo9">DESCRIPTION OF BUSINESS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc">We specialize in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc">In August 2020, we formed a wholly owned subsidiary, PDEX Franklin, LLC (“PDEX Franklin”), to hold title for an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”) that we acquired on November 6, 2020, in order to allow for the continued growth of our business. The consolidated financial statements include the accounts of the Company and PDEX Franklin and all significant inter-company accounts and transactions have been eliminated. This subsidiary has no separate operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"> </p>
CY2024	pdex	Revenue Recognition Sale Of Services RevenueRecognitionSaleOfServices	<p id="xdx_840_ecustom--RevenueRecognitionSaleOfServices_z44kmq7gs501" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0"><b><span id="xdx_861_z2EQUUnNSsd6">Net Sales</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify; text-indent: 3pc">Net sales consists of the sale of products and services, as well as shipping and handling billed to our customers and is net of volume rebates and discounts and excludes sales tax.</p>
CY2024	us-gaap	Profit Loss ProfitLoss	118000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	108000	usd
CY2024	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p id="xdx_846_eus-gaap--GuaranteesIndemnificationsAndWarrantiesPolicies_zIUDQAMklcCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_863_zRuqI1UBXO1k">Warranties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify; text-indent: 3pc">Certain of our products are sold with a warranty that provides for repairs or replacement of any defective parts for a period, generally one to two years, after the sale. At the time of the sale, we accrue an estimate of the cost of providing the warranty based on prior experience with such factors as return rates and repair costs, which factors are reviewed quarterly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify; text-indent: 3pc">The warranty accrual is based on historical costs of warranty repairs and expected future identifiable warranty expenses and is included in accrued expenses in the accompanying consolidated balance sheets. Warranty expenses are included in cost of sales in the accompanying consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair costs and warranty return rates and are included in current period warranty expense.</p>
CY2024Q2	us-gaap	Other Inventory In Transit OtherInventoryInTransit	275000	usd
CY2023Q2	us-gaap	Other Inventory In Transit OtherInventoryInTransit	637000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zJWP6aKgW8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86A_z8fpPuQu9qcg">Concentration of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-align: justify; text-indent: 3pc">Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, and trade receivables. We place our cash and cash equivalents with major financial institutions. At June 30, 2024 and 2023, and throughout the fiscal years then ended, we had deposits in excess of federally insured limits. Credit sales are made to medical device distributors, original equipment manufacturers, and resellers throughout the world, and sales to such customers account for a substantial portion of our trade receivables. While such receivables are not collateralized, we evaluate their collectability based on several factors including customers’ payment histories.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zIxppZJShO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0pc"><b><span id="xdx_86C_zbKFnjsOpnw8">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-align: justify; text-indent: 3pc">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-align: justify; text-indent: 3pc">Our operations are affected by numerous factors including market acceptance of our products, supply chain disruptions, changes in technologies, and new laws, government regulations, and policies. We cannot predict what impact, if any, the occurrence of these or other events might have on our operations. Significant estimates and assumptions made by management include, but are not limited to, revenue recognition, share-based compensation, the allowance for credit losses, accrued warranty expense, investments, inventory valuation, the carrying value of long-lived assets, and the recoverability/extinguishment of deferred income tax assets and liabilities.</p>
CY2024	us-gaap	Advertising Expense AdvertisingExpense	14000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	4000	usd
CY2024	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	786000	usd
CY2023	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	2695000	usd
CY2024	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	53058000	usd
CY2023	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	43392000	usd
CY2024	us-gaap	Revenues Revenues	53844000	usd
CY2023	us-gaap	Revenues Revenues	46087000	usd
CY2024Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	710000	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	1545000	usd
CY2024	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	-691000	usd
CY2023	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	-1710000	usd
CY2024	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	-43000	usd
CY2023	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	-51000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	262000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	494000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1013000	usd
CY2024	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	267000	usd
CY2023	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	781000	usd
CY2024	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue	-253000	usd
CY2023	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue	-1794000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	14000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4217000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1134000	usd
CY2024Q2	pdex	Marketable Securities Monogram Warrant Noncurrent MarketableSecuritiesMonogramWarrantNoncurrent	0	usd
CY2023Q2	pdex	Marketable Securities Monogram Warrant Noncurrent MarketableSecuritiesMonogramWarrantNoncurrent	6160000	usd
CY2024Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1563000	usd
CY2023Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1361000	usd
CY2024Q2	us-gaap	Marketable Securities MarketableSecurities	5780000	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	8655000	usd
CY2024Q2	pdex	Available For Sale Securities Amortized Costs AvailableForSaleSecuritiesAmortizedCosts	3964000	usd
CY2023Q2	pdex	Available For Sale Securities Amortized Costs AvailableForSaleSecuritiesAmortizedCosts	2714000	usd
CY2024	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1800000	usd
CY2024	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	2100000	usd
CY2024	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	261000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	219000	usd
CY2023	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	286000	usd
CY2023	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	67000	usd
CY2024Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	987000	usd
CY2023Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	1134000	usd
CY2023Q4	us-gaap	Cash Cash	1250000	usd
CY2023Q4	pdex	Common Stock Shares CommonStockShares	1828551	shares
CY2023Q4	pdex	Exercise Unrealized Loss Investments ExerciseUnrealizedLossInvestments	38000	usd
CY2024Q2	pdex	Fair Value Of Monogram Common Stock FairValueOfMonogramCommonStock	3200000	usd
CY2023Q2	us-gaap	Share Price SharePrice	3.98
CY2023	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	0.69
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2Y5M23D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.600	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0468	pure
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6703000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	8824000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	5103000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	3686000	usd
CY2024Q2	pdex	Inventory Sub Assemblies InventorySubAssemblies	2342000	usd
CY2023Q2	pdex	Inventory Sub Assemblies InventorySubAssemblies	2387000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1121000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1270000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	15269000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	16167000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	6499000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	6499000	usd
CY2024Q2	pdex	Accumulated Depreciation AccumulatedDepreciation	344000	usd
CY2023Q2	pdex	Accumulated Depreciation AccumulatedDepreciation	250000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6155000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6249000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14288000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13390000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9264000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8311000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5024000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5079000	usd
CY2024	us-gaap	Depreciation Depreciation	1038000	usd
CY2023	us-gaap	Depreciation Depreciation	727000	usd
CY2024Q2	pdex	Retired Assets RetiredAssets	85000	usd
CY2023Q2	pdex	Retired Assets RetiredAssets	760000	usd
CY2024Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	208000	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	208000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	154000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	127000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	54000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	81000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	30000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	668000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	650000	usd
CY2024Q2	pdex	Unvouchered Inventory In Transit Current UnvoucheredInventoryInTransitCurrent	276000	usd
CY2023Q2	pdex	Unvouchered Inventory In Transit Current UnvoucheredInventoryInTransitCurrent	637000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	301000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	216000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	353000	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	400000	usd
CY2024Q2	pdex	Operating Lease Liability Currents OperatingLeaseLiabilityCurrents	455000	usd
CY2023Q2	pdex	Operating Lease Liability Currents OperatingLeaseLiabilityCurrents	416000	usd
CY2024Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	277000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	200000	usd
CY2024Q2	pdex	Accrued Losses On Development Contracts Current AccruedLossesOnDevelopmentContractsCurrent	840000	usd
CY2023Q2	pdex	Accrued Losses On Development Contracts Current AccruedLossesOnDevelopmentContractsCurrent	480000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	189000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	136000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3359000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3135000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	200000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	340000	usd
CY2024	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	197000	usd
CY2023	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	161000	usd
CY2024	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	70000	usd
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-109000	usd
CY2024	pdex	Product Warranty Accrual Amortization ProductWarrantyAccrualAmortization	190000	usd
CY2023	pdex	Product Warranty Accrual Amortization ProductWarrantyAccrualAmortization	192000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	277000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	200000	usd
CY2024	us-gaap	Product Warranty Expense ProductWarrantyExpense	267000	usd
CY2023	us-gaap	Product Warranty Expense ProductWarrantyExpense	52000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1493000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1745000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	577000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	345000	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1210000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6000	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-353000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	258000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	507000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2354000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2634000	usd
CY2024	pdex	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Tax Rate IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestTaxRate	1	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9428000	usd
CY2023	pdex	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Tax Rate IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestTaxRate	1	pure
CY2024	pdex	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rates IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRates	553000	usd
CY2024	pdex	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2023	pdex	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rates IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRates	1979000	usd
CY2023	pdex	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	212000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	672000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2024	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	214000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.08	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	229000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.02	pure
CY2024	pdex	Uncertain Tax Positions UncertainTaxPositions	88000	usd
CY2024	pdex	Uncertain Tax Position UncertainTaxPosition	-0.03	pure
CY2023	pdex	Uncertain Tax Positions UncertainTaxPositions	119000	usd
CY2023	pdex	Uncertain Tax Position UncertainTaxPosition	-0.01	pure
CY2024	pdex	Income Tax Reconciliation Share Based Compensation IncomeTaxReconciliationShareBasedCompensation	-2000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0	pure
CY2023	pdex	Income Tax Reconciliation Share Based Compensation IncomeTaxReconciliationShareBasedCompensation	114000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01	pure
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	42000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.01	pure
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	165000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.01	pure
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	507000	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.19	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2354000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22000	usd
CY2024Q2	pdex	Deferred Tax Assets Research And Other Credits DeferredTaxAssetsResearchAndOtherCredits	65000	usd
CY2023Q2	pdex	Deferred Tax Assets Research And Other Credits DeferredTaxAssetsResearchAndOtherCredits	65000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	146000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	122000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	309000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	267000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1008000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	814000	usd
CY2024Q2	pdex	Section174 Capitalization Section174Capitalization	738000	usd
CY2023Q2	pdex	Section174 Capitalization Section174Capitalization	830000	usd
CY2024Q2	pdex	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	488000	usd
CY2023Q2	pdex	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	599000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	596000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	351000	usd
CY2024Q2	pdex	Deferred Tax Assets Deferred State Tax DeferredTaxAssetsDeferredStateTax	5000	usd
CY2023Q2	pdex	Deferred Tax Assets Deferred State Tax DeferredTaxAssetsDeferredStateTax	31000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3378000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3101000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3288000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3010000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	675000	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	767000	usd
CY2024Q2	pdex	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	439000	usd
CY2023Q2	pdex	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	546000	usd
CY2024Q2	pdex	Deferred Tax Liabilities Deferred State Tax DeferredTaxLiabilitiesDeferredStateTax	78000	usd
CY2023Q2	pdex	Deferred Tax Liabilities Deferred State Tax DeferredTaxLiabilitiesDeferredStateTax	-0	usd
CY2024Q2	pdex	Deferred Tax Assets Unrealized Gain On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedGainOnAvailableforSaleSecuritiesGross	541000	usd
CY2023Q2	pdex	Deferred Tax Assets Unrealized Gain On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedGainOnAvailableforSaleSecuritiesGross	1705000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1733000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3018000	usd
CY2024Q2	pdex	Deferred Tax Asset Liabilities Net DeferredTaxAssetLiabilitiesNet	1555000	usd
CY2023Q2	pdex	Deferred Tax Asset Liabilities Net DeferredTaxAssetLiabilitiesNet	-8000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7000	usd
CY2024Q2	pdex	Unrecognized Tax Benefit UnrecognizedTaxBenefit	262000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	345000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	509000	usd
CY2024	pdex	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions On Federal Tax UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositionsOnFederalTax	15000	usd
CY2023	pdex	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions On Federal Tax UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositionsOnFederalTax	16000	usd
CY2024	pdex	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Upon State Tax UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositionsUponStateTax	17000	usd
CY2023	pdex	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Upon State Tax UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositionsUponStateTax	19000	usd
CY2024	pdex	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Position UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPosition	3000	usd
CY2023	pdex	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Position UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPosition	-95000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	118000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	104000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	262000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	345000	usd
CY2024	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	41000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4398000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1451000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1508000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	908000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	235000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3456000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	11956000	usd
CY2024Q2	pdex	Operating Lease Liability Currents OperatingLeaseLiabilityCurrents	455000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	535000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	551000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	567000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	143000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1796000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	158000	usd
CY2024Q2	pdex	Operating Lease Liabilities OperatingLeaseLiabilities	1638000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y3M
CY2023Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4Y3M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053	pure
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	519000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	504000	usd
CY2024	pdex	Lease And Rental Expenses LeaseAndRentalExpenses	559000	usd
CY2023	pdex	Lease And Rental Expenses LeaseAndRentalExpenses	563000	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y
CY2024	us-gaap	Net Income Loss NetIncomeLoss	2127000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	7074000	usd
CY2024	pdex	Weightedaverage Share Outstanding WeightedaverageShareOutstanding	3499000	shares
CY2023	pdex	Weightedaverage Share Outstanding WeightedaverageShareOutstanding	3571000	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.98
CY2024	us-gaap	Net Income Loss NetIncomeLoss	2127000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	7074000	usd
CY2024	pdex	Weightedaverage Shares Outstanding WeightedaverageSharesOutstanding	3499000	shares
CY2023	pdex	Weightedaverage Shares Outstanding WeightedaverageSharesOutstanding	3571000	shares
CY2024	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	72000	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	66000	shares
CY2024	pdex	Weightedaverage Shares Used In Calculation Of Diluted Earnings Per Share WeightedaverageSharesUsedInCalculationOfDilutedEarningsPerShare	3571000	shares
CY2023	pdex	Weightedaverage Shares Used In Calculation Of Diluted Earnings Per Share WeightedaverageSharesUsedInCalculationOfDilutedEarningsPerShare	3637000	shares
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.95
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001553350-24-000079-index-headers.html	Edgar Link	pending
0001553350-24-000079-index.html	Edgar Link	pending
0001553350-24-000079.txt	Edgar Link	pending
0001553350-24-000079-xbrl.zip	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23.htm	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
ex4x1.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pdex-20240630.xsd	Edgar Link	pending
pdex_10k-063024.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
pdex-20240630_lab.xml	Edgar Link	unprocessable
pdex-20240630_pre.xml	Edgar Link	unprocessable
pdex_10k-063024_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pdex-20240630_cal.xml	Edgar Link	unprocessable
pdex-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PDEX
PRO DEX INC Stock $pdex

2024 Q3 Form 10-K Financial Statement

#000155335024000079 Filed on September 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX PRO DEX INC Stock $pdex

2024 Q3 Form 10-K Financial Statement

#000155335024000079 Filed on September 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX
PRO DEX INC Stock $pdex